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|Summary|
Statins are the lipid-lowering drug family of first choice in 
situations of hypercholesterolemia or mixed dyslipidemia 
with predominant increase in cholesterol. The evidence 
shows conclusively that each one of the commercially 
available statins have proven benefits on outcomes of car-
diovascular morbidity and mortality. However, rosuvastatin 
has certain pharmacokinetic efficacy and cost-effectiveness 
characteristics that make it an attractive molecule to be 
the statin of choice in patients at high cardiovascular risk.
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Resumen
Las estatinas son la familia farmacológica hipolipemiante 
de primera opción en situaciones de hipercolesterolemia o 
dislipiemia mixta con predominio de aumento en el coles-
terol. La evidencia demuestra contundentemente que cada 
una de las estatinas disponibles en el mercado ha mostrado 
beneficios en desenlaces de morbi-mortalidad cardiovascular. 
Sin embargo, la rosuvastatina presenta ciertas caracterís-
ticas farmacocinéticas de eficacia y de costo-efectividad 
que la hacen una molécula atractiva para ser la estatina 
de elección en pacientes de alto riesgo cardiovascular.
Palabras clave: Inhibidores de Hidroximetilglutaril-CoA 
Reductasas, enfermedades ardiovasculares, dislipidemias, 
evaluación de Costo-Efectividad (DeCS).
Feliciano-Alfonso JE. Rosuvastatin: Role in Cardiovascular High-risk 
Patient. Rev. Fac. Med. 2013; 61: 41-51.
Introduction
Statins competitively inhibit hidroxi methylglutaryl 
coenzyme A (HMG CoA) reductase, the enzyme invol-
ved in cholesterol endogen production that regulates its 
formation velocity (2), thereby increasing the availability 
of cholesterol low density lipoproteins (LDL-C) in the 
cell membrane and allowing for its levels to decrease 
(Figure 1).
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Figure 1. 5-Step statin action mechanisms: When LDL-C levels are high 
(1), a statin is given in order to inhibit the HMG-CoA reductase in the 
hepatocyte (2).  This leads to intracellular cholesterol reduction thereby 
eliciting the activation of a transcription factor named SREBP (Sterol 
and Retinol Binding Protein) and its translocation to the nucleus (3). This 
way, LDL-C receptors expression is promoted (4) and its removal from 
circulation is increased.
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HMG-CoA reductase inhibitors are the first-choice drugs 
(against other lipid-lowering drugs such as the bile acids 
sequestering agents or ezetimibe) in hypercholesterolemia 
and mixed dyslipidemia patients with predominance of in-
creased cholesterol. The decision for use, according to the 
addenda of NCEP-ATP III (National Cholesterol Educatio-
nal Program–Adult Treatment Panel III) clinical guidelines 
recommendations is dependent on the cardiovascular risk 
(Figure 2), specified in four levels (2,3).
Very high risk
It occurs when there exists a previous cardiovascular 
episode (myocardial infarction), stable or instable angina, 
coronary artery procedure such as angioplasty or bypass, 
of otherwise clinically significantly myocardial ischemia 
evidence) involving more than one risk factor (e.g. diabetes, 
hypertension, persistent smoking).
High risk
It occurs under prior coronary disease conditions or its equivalent 
(peripheral artery disease, aneurism of abdominal aorta, carotid 
disease (including transient ischemic attack or apoplexy of carotid 
origin or >50% obstruction of any carotid artery) or primary athero-
genic dyslipidemia), as well as in those people which multiple risk 
factors involve >20% risk of 10 years coronary disease.
Intermediate risk
Occurs in people with metabolic syndrome or which multiple risk 
factors involve 10 to 20% coronary disease 10 year risk.
Latent risk
Exists in those people which risk factor involve <10% 10-year 
coronary disease risk.
Figure 2.  LDL-C goal levels and recommendations for use of statins for each of four 
(coronary) cardiovascular risk levels. TLC: Therapeutic Lifestyle Changes. 
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Table 1. Male cardiovascular risk stratification.  For instance, a smoker patient (5 
points) aged 47 (3 points), 220 mg/dL total cholesterol level (5 points) and 43 mg/
dL HDL cholesterol with  untreated systolic blood pressure 135 mmHg levels (1 
point), will have 15 scoring, which means that its (coronary) cardiovascular risk 
is high because its percent is 20%.
Table 2. Women cardiovascular risk stratification. For instance, any non 
smoker woman (0 points) aged 65 (12 points), with 240 mg/dL (3 points) total 
cholesterol levels (3 points) and 55 mg/dL (0 points) HDL cholesterol, with 140 
mmHg (5 points) systolic blood pressure, will have 20 score, which means 
her cardiovascular risk to be intermediate inasmuch as her score is 11%.
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The risk factors, taking into account for cardiovascular risk 
stratification based on the tables derived from Framingham, study 
(Tables 1 & 2) are the following: sex (the tables and scores are 
different for male and female), age (the older age the higher risk 
score), total cholesterol (which in turn is dependent of the age), 
HDL cholesterol (which becomes protective, i.e., decreases score 
when its levels raise to 60 mg/dL), smoking habit (taken in a 
dichotomy manner: smoking or no-smoking), and systolic blood 
pressure (the score of which will vary whether or not patient is 
under pharmacological treatment).
 This classification, however, implies some limitations as it only 
establishes the risk of coronary events (myocardial infarction due 
to coronary disease) and fails to take into account other significant 
cardiovascular event, such as cerebrovascular disease. Additionally 
criticism against the paradigm “to treat until the target” the LDL-C, 
requesting that the next clinical guides of the ATP IV recommend 
the treatment with statins in accordance with individual cardiovas-
cular risk independent from LDL cholesterol levels (4).
Rosuvastatin vs other statins
Statins show similar chemical structures as they all show 
an analogy similar the radical beta-hydroxyl-beta methyl 
glutaryl (HMG). Rosuvastatin, however, has a methyl-
sulfonamide group which allows more interaction with some 
amino acid residues of the MHG CoA reductase, and this 
way to have a high affinity for the active site of the enzyme 
(5). Additionally, rosuvastatin hepatic selectivity shall be 
taken into account as it is a relatively hydrophilic (the same 
as pravastatin), compared to other statins, and therefore its 
uptake by other type of different cells would be limited (6). 
In fact, classic head-to-head randomized controlled clinical 
trials (RCT) such as STELLAR (Statin Therapies for Eleva-
ted Lipid Levels compared Across doses to Rosuvastatin), 
have shown rosuvastatin to be the inhibitor of HMGCoA 
reductase significantly achieving greater LDL-C decreases 
(Table 3)(7).
Table 3. Comparison Statins of pharmacological properties (5,6) and efficacy (ref. STELLAR study (7), 
excepting for fluvastatin and lovastatin ref. CURVES study (8). LDL-C: LDL cholesterol; HDL-C: HDL-C; TG: 
Triglycerides.
Characteristics 
Statin
Min Dose % LDL-C 
Reduction
% HDL-C 
Increase
%  TG 
Reduction
Cytochrome 
P450 
Metabolism
Half-life 
(hrs)
Fluvastatin 20 mg 17% 1% 5% 2C9 1-3
Pravastatin 10 mg 20% 3% 8% --- 1-3
Simvastatin 10 mg 28% 5% 12% 3 A4 2-5
Lovastatin 20 mg 29% 7% 12% 3 A4 2-5
Atorvastatin 10  mg 37% 6% 20% 3 A4 14
Rosuvastatin 10 mg 46% 8% 20% 2C9/2C19 20
Table 4. Mean ± standard deviation changes of lipidic parameters with different dose of statins and percentage of patients reaching the goal 
of LDL-C <70 mg/dL or<100mg/dL when their LDL-C base is ≥ 160 mg/dL (*) or between130 and 159 mg/dL (**). σ = represents less than 
10 patients. ND= No Available (Ref. 9).
Statin Rosuvastatin Atorvastatin Simvastatin
Dose 5 mg 10 mg 20 mg 40 mg 10 mg 20 mg 40 mg 80 mg 10 mg 20 mg 40 mg 80 mg
LDL-C -38.8 ± 0.9 -44.1± 0.6 -49.5± 0.5 -54.7 ± 0.4 -35.5± 0.6 -41.4 ± 0.5 -46.2 ± 0.5 -50.2 ± 0.4 -27.4 ± 1.4 -33.0 ± 0.6 -38.9 ± 0.9 -45.0 ± 1.0
Non HDL-C -35.4 ± 0.8 -40.2 ± 0.5 -45.1 ± 0.4 -49.9 ± 0.3 -32.8 ± 0.5 -38.2 ± 0.5 -42.6 ± 0.5 -46.6 ± 0.4 -24.8 ± 1.2 -30.1 ± 0.5 -35.0 ± 0.8 -40.5 ± 0.9
TG -15.2 ± 1.4 -18.7 ± 0.5 -20.1 ± 0.7 -21.9 ± 1.0 -16.4 ± 0.5 -18.9 ± 0.6 -20.7 ± 1.2 -25.0 ± 1.1 -9.3 ± 2.5 -12.7 ± 0.7 -13.3 ± 1.4 -14.5 ± 1.8
% patients 
with LDL-C < 
70 mg/dL *
3.2% 11.4% 20.5% 31.7% 2.0% 4.1% 9.8% 18.1% 0% 1.6% 1.5% 4.0%
% patients 
with LDL-C < 
70 mg/dL**
0%σ 33.0% 57.2% 67.6% 8.8% 26.2% 45.2% 52.4% 0%σ 7.0% 19.9% ND
% patients 
with LDL-C < 
100 mg/dL *
38.0% 56.8% 64.5% 74.1% 28.7% 45.0% 56.6% 71.4% 8.8% 24% 34.2% 38.5%
% patients 
with LDL-C < 
100mg/dL**
66.7%σ 75.9% 90.1% 95.4% 62.1% 83.8% 91.1% 86.4% 50.0%σ 57.3% 76.7% ND
 
Rosuvastatin: 41-5144 
This last assertion was confirmed by a meta analysis 
(VOYAGER) of data from more than 32000 individual 
patients derived from 37 studies (9), which determined the 
ratio between the increment of dosing from three statins 
frequently used in the clinical practice (rosuvastatin vs. 
atorvastatin vs. simvastatin) and their capacity to increase 
atherogenic parameter reduction, as well as the achieve-
ment of treatment goals established (see below). It was 
demonstrated that by duplicating statin dose, a 4% and 7% 
additional reduction of LDL-C was obtained. In the same 
way, it was documented that both statin dose and LDL-C 
level base are predictors to reach treatment goals in high-
risk patients (Table 4).
Rosuvastatin ensures HMG CoA reductase sustained 
inhibition as it has more extended half-life (20 hrs) among 
statins (Table 3) (6). This characteristic makes it to outstand 
as a valuable therapeutic option in the intolerance context 
of statins as described in several case report (10) and retros-
pective studies (11,12) where up to 72.5% of patients with 
intolerance resolve their symptoms by delivering rosuvasta-
tin once every other day such dosing (5.6mg mean) reducing 
LDL cholesterol by 34.5%. In fact, two controlled clinical 
studies assessed rosuvastatin 10 or 20 mg once every other 
day versus rosuvastatin 10mg/daily (13,14) during six wee-
ks, resulting in LDL-C reduction up to 48.5%for daily dose 
and up to 40.9% for 20 mg once every other day (p=0.012). 
Rosuvastatin also is advantageous because of its minimum 
metabolism through P450 cytochrome (CTP), especially 
through CYP2C9 and CYP2C19 isoenzyme CYP3A4, as 
most of the statins (simvastatin, lovastatin and atorvastatin), 
which is involved in a broad variety of drug interactions (6). 
Such drugs usually present in patients under therapy with 
verapamil, diltiazem, and macrolides, such as erythromycin 
or clarithromycin, among others (15).
Statins are usually well tolerated. Most common adverse 
effects include myalgia, constipation, asthenia, abdominal 
pain, and nausea (16). Several meta-analysis have found all 
statins to have a similar safety profile (17,18), the most fre-
quent adverse effects occurring with higher doses of statins 
(19). Someone could believe, however, that rosuvastatin 
could have difference related to adverse as against other 
statins. Notwithstanding, a meta-analysis of four pharma-
coepidemiological studies conducted on several interna-
tional databases that evaluated rosuvastatin safety profile 
versus other statins, evidenced that there was no higher 
incidence of rare adverse events such as hospitalizations 
due to myopathies (0.5 episodes per 10000 years-patient; 
IC95%: -0.6 a 1.6), rhabdomyolysis (0.7 episodes per 10000 
years-patient; IC95%: -0.3 a 1.6), acute renal failure (-0.2 
episodes per 10000 years-person; IC95%:-2.9 a 2.5) or 
acute hepatic damage (-0.8 cases per 10000 years-person; 
IC95%: -1.8 a 0.2) with the use of rosuvastatin (20). What 
certainly was found is that the therapy with most of statins 
can impair glycemic control, or slightly increase diabetes 
mellitus risk by 9% average (OR=1.09; IC95%: 1.02 a 1.17)
(18, 21). Due to occurrence, FDA (US Food and Drug Agen-
cy) has added up a warning in the labeling from all statins 
advising that they may increase glycemia and hemoglobin 
A1c levels, recognizing, however, statins cardiovascular 
benefits overweight such mildly increases. (22).
Those benefits are important cardiovascular (CV) mor-
bidity and mortality reductions (CV) evidenced by all and 
any of the statins in several different scenarios (Table 5). 
In fact, a meta-analysis involving some number of stu-
dies included in Table 4, determined that a LDL-C reduction 
by 39 mg/Dl was associated to 21% reduction of the inci-
dence at 5-year of major coronary events, revascularization, 
and cerebrovascular accident, as well as 12% mortality 
reduction by all causes, regardless of baseline lipidic values 
(35) and such benefits are extended to populations with or 
without coronary disease established (36). Other effects 
additional to LDL-C reduction by statins include enhan-
cement of endothelial dysfunction, diminution of vascular 
inflammation, stabilization or regression of atherosclerotic 
plate and platelet aggregation inhibition (37). 
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Table 5. Studies supporting the use of statins by demonstrating the prevention of cardiovascular morbidity-mortality. TC: Total 
cholesterol. hsCRP: High sensitive C reactive protein.
Scenario Study (reference) Used statin / Comparator / 
Duration
Relative risk significant reduction 
of:
With recent Acute Myocardial Infarction
3086 patients with coronary event 24 to 96 before MIRACL (23) Atorvastatin 80 mg vs. placebo for 
16-weeks
26% ischemia recurrence
4162 patients with coronary event 10 days before PROVE-IT (24) Atorvastatin 80 mg vs. pravastatin 
40 mg for 24months
16% cardiovascular events
CV high-risk patients 
4444 patients with prior coronary disease and 
hypercholesterolemia (CT:212 a 309 mg/dL)
4S (25) Simvastatin 40 mg vs. placebo for 
5.4 year
30% total death
Death due to coronary disease 42%
Coronary events 34%
4154 patients with prior coronary disease and 
“normal” cholesterol levels: LDL-C (115-174 mg/dL)
CARE (26) Pravastatin 40 mg vs. placebo for 
5 years
24% coronary events
31% Cerebrovascular accidents
Angioplasty 23%
9014 patients with prior coronary disease and 
cholesterol “slightly raised” levels (CT: 150-270 mg/dL)
LIPID (27) Pravastatin 40 mg vs. placebo for 
6.1 years
Total death 22%
Death due to coronary disease 25%
20536 patients coronary of equivalent disease (Arterial 
peripheral or diabetes) “normal” cholesterol levels 
(>135 mg/dL)
HPS (28) Simvastatin 40 mg vs. placebo for 
5 years
Total Mortality 12.9%
Fatal or non fatal infarction 26%
Cerebrovascular accident 24%
10305 patients with not prior heart disease but with 
some risk factors and cholesterol “normal” risk factors 
(CT < 250 mg/dL)
ASCOT-LLA (29) Atorvastatin vs. placebo for 3.3 
years
Fatal or non fatal infarction 36%
All events CV 21%
Cerebrovascular events 27%
5804 Elderly (>70 year)with CV high risk PROSPER (30) Pravastatin 40 mg vs. placebo for 
3.5 years
Coronary events 15%
Fatal or non-fatal infarction 19%
Death for coronary disease 24%
2838 patients with diabetes mellitus 2 in primary 
prevention with normal LDL-C (<160 mg/dL)
CARDS (31) Atorvastatin 10 mg vs. placebo for 
3.9 years
Cardiovascular events 32%
Coronary events 36%
Cerebrovascular events 48%
Patients of Primary prevention
6595 patients of primary prevention with 
hypercholesterolemia (LDL-C: 174 a 232 mg/dL)
WOSCOPS (32) Pravastatin 40 mg vs. placebo for 
4.9 years
Fatal or non fatal infarction 31%
Death due to coronary disease 29%
5608 patients of primary prevention with “average of 
cholesterol” levels  (LDL-C: 130 to 170g/dL)
AFCAPS/TexCAPS (33) Lovastatin 40 mg vs. placebo for 
5.2 years
Coronary  events 33%
Fatal or non-fatal infarction 40%
17802 patients of primary  prevention with LDL-C 
<130 mg/dL and hsCRP ≥2.0 mg/L levels
JUPITER (34) Rosuvastatin 20 mg vs. placebo for 
1.9 years
Cardiovascular events 44%
Myocardial infarction 54%
Cerebrovascular  accident 48%
It should be stressed that the LUNAR (Limiting Under-
treatment of Lipids in Acute Coronary Syndrome with Rosu-
vastatin) (39) study which compared head-to-head atorvastatin 
80mg/day (atorva 80) peak dose as against rosuvastatin 20 mg/
day (rosu 20) and 40 mg/day (rosu 40) in hospitalized patients 
due to acute coronary syndrome within 48 h of the beginning 
of ischemic symptoms. In the Figure 3 below, the efficacy of 
LDL lowering and HDL increase is shown. Adverse effects 
related to treatment were similar for the three groups 9.4% 
for rosu20, 14.8% for rosu 40 and 15.6% for atorva 80 and 
included myalgias, fatigue, and headache, inter alia. Treatment 
discontinuation due to adverse effect was 3.7% for rosu 20, 
6.1% for rosu 40 and 9.3% for atorva 80. Cardiovascular 
events were infrequent in the three groups (3.4% for rosu20, 
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In the scenario where atorvastatin (MIRACL and PROVE 
IT studies (23,24) was successful, it was determined that ro-
suvastatin carries more people to the goal: SPACE ROCKET 
(Secondary Prevention of Acute Coronary Events – Reduction 
of Cholesterol to Key European Targets) study evaluated the 
lipid-lowering effects of rosuvastatin 10 mg/day vs. simvasta-
tin 40 mg/day for three months in the emergence context due 
to an acute myocardial infarction in the previous two weeks 
(38). A higher number of subjects randomized to rosuvastatin 
(45%) reached the goal of LDL-C <70mg/dL compared to 
those subjects with simvastatin therapy (37.8%; p=0.007), 
with a hepatic, renal and muscular similar profile.
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1.9% for rosu40 and 2.2% for atorva 80), this way showing 
higher LDL-C reductions with rosu 40 versus atorva 80, with 
a similar safety profile.
Figure 3. Percentage of mean (± standard deviation) change in 
LDL-C and HDL-c for the three LUNAR study treatment groups. 
Atorva 80: atorvastatin 80mg/day, Rosu 20: rosuvastatin 20mg/
day, Rosu 40: rosuvastatin 40mg/day (39).
Several RCTs such as PULSAR (Prospective study to 
evaluate the Use of Low doses of the Statins Atorvastatin 
and Rosuvastatin) (40), MERCURY II (Measuring Effective 
Reduction in Cholesterol Using Rosuvastatin therapy II) 
(41) and POLARIS (Prospective Optimization of Lipids 
by Atorvastatin or Rosuvastatin Investigated in high risk 
Subjects with hypercholesterolemia) (42) indicated the su-
periority of rosuvastatin over other statins to reach the goals 
of lipidic parameters en patients with cardiovascular risk. 
We emphasized on the studies of the series DISCOVERY 
(Direct Statin Comparison of LDL-C Values: an Evaluation 
of Rosuvastatin therapy), a set of nine independent studies 
the general purpose of which was to compare the efficacy 
of rosuvastatin 10 mg/day versus other statins (according 
to the appropriate initial dose of the one of them) to reach 
the goals recommended in high cardiovascular risk patients 
(cardiovascular risk at 10 years>20%, prior myocardial 
acute infarction or an equivalent atherosclerotic disease) 
(43-51). In Table 6, a summary of the findings of those stu-
dies is found. All of the studies had a safety profile similar 
among the statins involved. The study DISCOVERY PEN-
TA (50) evaluated specifically South America populations 
(Brazil, Mexico, Colombia and Venezuela) and Portugal: 
1124 patients with hypercholesterolemia (50% out of which 
were cardiovascular high-risk patients) were authorized to 
receive rosuvastatin 10mg/day vs. atorvastatin 10mg/day. 
LDL-C goals, according to NCEP-ATP III were obtained 
by 71.2% in rosuvastatin group and 61.4% in the other 
group (p<0.001).
The DISCOVERY BELUX study is worth of especial 
mention. This study was conducted in Belgium and Luxem-
bourg and its objective was to evaluate how many CV high 
risk patients reached LDL cholesterol goal (in this  event 
<115 mg/dL, according to the protocol of study and the goals 
of European Atherosclerosis Society (EAS)by that time) after 
randomization to rosuvastatin 10 mg/day or atorvastatin 10 
mg/day. In the first group 85% of patients reached the goal 
versus 67% of the second group after 12 weeks of treatment. 
Interestingly, those patients failing to reach the goal with 
rosuvastatin 10 mg/day and with atorvastatin 10 mg, were 
switched to a rosuvastatin dose 20 mg/day and 10 mg/day, 
respectively, during 12 additional weeks. This resulted that 
additionally at the end of such period, 57% of the first group 
and 65% of the second group reached LDL-C goal. This study 
was the only made in the DISCOVERY series that conducted 
an economic evaluation from the payer’s perspective and 
found that rosuvastatin 10 mg/day is more cost-effective 
than atorvastatin 10 mg/day in this scenario (47). The study 
ECLIPSE (Evaluation to Compare Lipid-lowering effects 
of rosuvastatin and atorvastatin In forced titrated patients: 
a Prospective Study of Efficacy and tolerability), on its side, 
assessed the efficacy of the double rosuvastatin dose 10 mg 
and atorvastatin 10 mg every 6 weeks, until reaching the peak 
dose of both two medicaments (40 and 80 mg, respectively) 
to reach the LDL-C goals (<100 mg/dL) in1036 patients of 
cardiovascular with hypercholesterolemia high risk. At the 
end of 24 weeks of treatment, 83.6% of patients randomized 
to rosuvastatin and 74.6% patients with atorvastatin reached 
LDL-C goal (p<0.001). In fact, since the first 6 weeks with 
the initial and peak dosing of rosuvastatin 10 mg/day and 
atorvastatin 10 mg/dL, the differences between the several 
percentages of patients who reached the goal with such 
treatments was remarkable (52.8% vs. 27.6%, respectively; 
p<0.001). Similarly, upon the completion of 24 weeks of 
follow-up, in the subgroup of patient in high cardiovascu-
lar risk, rosuvastatin carried more patients to the goal <70 
mg/dL (38.0%) than atorvastatin (20.2%; p<0.001). Once 
again, the differences between percent of CV very high risk 
patients in goal were significant since the first 6 weeks with 
the minimal dose of rosuvastatin (7.5%) versus atorvastatin 
(1.8%; p<0.001) (52).
In general, the group of studies known as DISCOVERY 
show that, after 12 weeks follow-up of cardiovascular high 
risk patients, rosuvastatin 10 mg/day may imply that sig-
nificantly far much more cardiovascular high-risk patients 
(between 50 to 75%) obtain LDL-C goal<100 mg/dL, as 
compared to atorvastatin 10 mg/day (25 to 55%) or simvas-
tatin 20 mg/day (18.5% to 50%). In the same way, according 
to the results from VOYAGER (9) meta-analysis, it shall 
be taken into account that the reaching the LDL baseline 
cholesterol and the dose of stating used (Table 4). 
Rev. Fac. Med. 2013 Vol. 61 No. 1: 41-51 47
Rosuvastatin: economic evaluation in cardiovascular high-
risk patient
Several economic evaluations based on STELLAR study 
with one year horizon time and under payer’s perspective of 
Canada and the United States (considering the percentage of 
change of lipidic parameters and the people reaching LDL-C 
goal), have evidenced that branding rosuvastatin in 10mg/
day dosing is more cost-effective than branding atorvastatin 
(10 and 20 mg/day) and simvastatin (20 and 40 mg/day) and 
pravastatin generics (20 and 40 mg/day (53-55).
In the same way, other economic evaluations made in 
Europe and North America have used clustered efficacy data 
from several rosuvastatin controlled clinical assays com-
pared head-to-head to other statins, concluding once again 
that rosuvastatin 10 mg/day is more cost-effective than other 
therapeutic options, such as atorvastatin 10mg/day, from the 
primary caregivers’ perspective in the United Kingdom (56).
It has been determined that for patients with increasingly 
higher coronary risk, the therapy with statins is more cost-
effective (57,58). And the question raised in this connection is 
whether rosuvastatin is more cost-effective than other statins, 
specifically in cardiovascular high-risk risk patients. The an-
swer is yes, and it was confirmed by DISCOVERY BELUX 
study (47), as did as well POLARIS study (42). Additionally, 
other study used a Markov model to Project the number of 
CV events and the cost associated to a high-risk population 
in several pharmacological treatment context, established 
that using rosuvastatin instead of other statins may reduce 
cardiovascular events in this type of population and saving 
cost for several US dollars of United States health systems 
(59). These results have been confirmed in other RCTs inclu-
ding subjects from other geographic locations, among which 
PULSAR study (38, 60). For example, in a study using Monte 
Carlo probabilistic simulation model and based on JUPITER 
study for long-term cost-effectiveness of rosuvastatin Brand 
(CRESTOR®) at 20 mg/day versus simvastatin or atorvastatin 
generics 40 mg/day for CV morbidity-mortality prevention in 
CV high-risk Sweden population (from Sweden health system 
payer’s perspective and a permanent time-horizon), found that 
the higher cost-effectiveness and cost-utility of rosuvastatin 
was basically by the number of CV prevented (60).
Rosuvastatin cost-effectiveness could be determined in the 
context of Latin America countries, where the cost of medici-
nal products varies from country to country, using RCT as a 
basis such as STELLAR or JUPITER studies, as made by other 
economic evaluations or otherwise, using RCT made in South 
American population, such as DISCOVERY PENTA study.
In conclusion, it is possible to assert that rosuvastatin is 
more advantageous than other statins with regard to its phar-
macokinetics, LDL-C reduction and percentage of patients 
reaching a goal, with a similar safety profile. Similarly, rosu-
vastatin has conclusively demonstrated in the several different 
economic evaluations to be the most cost-effective compared 
to other pharmacological options. By taking into account these 
assertions together with the quality of evidence found in the 
studies aforementioned; rosuvastatin could be considered as 
the first-choice for cardiovascular high-risk patients.
Table 6. Studies included in DISCOVERY series (Direct Statin Comparison of LDL-C Values: and Evaluation of Rosuvastatin therapy).
DISCOVERY 
THE NETHER-
LANDS/DUTCH
DISCOVERY 
TRIPLE 
COUNTRY
DISCOVERY 
ASIA
DISCOVERY 
ALFA
DISCOVERY 
BELUX
DISCOVERY 
BETA
DISCOVERY 
PENTA
DISCOVERY 
UK
Author / yr Bots y Kastelein 
2005 (43)
Strandberg at al 
2004 (44)
Zhu et al 2007 
(45)
Binbrek et al 
2006 (46)
Herregods et al 
2006 (47)
Laks et al 2008 
(48)
Fonseca et al 
2005 (50)
Middleton 
y Fuat 2006 
(51)
Population 1215 CV High 
risks patients
911 CV High 
risks patients
1482 CV High 
risks patients 
1506 CV High 
risks patients
938 CV High 
risks patients
504 CV High 
risks patients
1124 (50% CV 
High risks)
1874 CV 
High risks 
patients
Place / Length  Netherlands 12 
weeks
Iceland, Ireland 
and Finland 12 
weeks
Asia 12 weeks East Europe, 
Central America, 
Chile and Middle 
East12 weeks
Belgium and 
Luxembourg12 
weeks
Estonia12 
weeks
South America 
and Portugal 
12 weeks
England 12 
weeks
Drug given 1. Rosu 10 mg
2. Atorva 10 mg
3. Simva 20 mg
4. Prava 40 mg
1. Rosu 10 mg
2. Atorva 10 mg
1. Rosu 10 mg
2. Atorva 10 
mg
1. Rosu 10 mg
2. Atorva 10 mg
1. Rosu 10 mg
2. Atorva 10 mg
1. Rosu 10 mg
2. Simva 20 mg
1. Rosu 10 mg
2. Atorva 10 
mg
1. Rosu 10 
mg
2. Atorva 10 
mg
3. Simva 20 
mg
Outcomes (% 
patients with 
LDL-C <100 
mg/dL)
1. 50.2%
2. 24.9%
3. 26.3%
4. 18.5%
P<0.001 vs. rosu
1. ≈ 4%
2. ≈ 52%
P <0.001 vs. rosu
1. 65.8%
2. 49.5%
P<0.0001 vs. 
rosu*
1. 57.5%
2. 39.2%
P<0.001 vs. rosu
1. 71.8%
2. 46.5%
P<0.05 vs. rosu*
1. 44.5%
2. 22.2%
P<0.001 vs. 
rosu *
1. 71.2%
2. 61.4%
P<0.0001 vs. 
rosu
1. 76%
2. 55%
3. 50%
P<0.0001 
vs. rosu
* LDL-C goal < 115 ó 100 mg/dL with established CV disease or DM. 
Rosuvastatin: 41-5148 
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